초록 ▼

The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (e.g., fentanyl hydrochloride), preferably in a hydrogel formulation, for use in an electrotransport device (10).

The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (e.g., fentanyl hydrochloride), preferably in a hydrogel formulation, for use in an electrotransport device (10). In accordance with the present invention, a transdermal electrotransport delivered dose of fentanyl/sufentanil is provided which is sufficient to induce analgesia in (e.g., adult) human patients suffering from moderate-to-severe pain as associated with major surgical procedures.

대표청구항 ▼

[ What is claimed is:] [1.]1. A patient-worn device for transdermally delivering fentanyl by electrotransport and which allows a patient who is suffering from pain and who is wearing the device to obtain self-administered analgesia, the device comprising:a donor reservoir hydrogel formulation compri

[ What is claimed is:] [1.]1. A patient-worn device for transdermally delivering fentanyl by electrotransport and which allows a patient who is suffering from pain and who is wearing the device to obtain self-administered analgesia, the device comprising:a donor reservoir hydrogel formulation comprised of fentanyl in a form to be delivered solely by electrotransport;a counter reservoir;a source of electrical power electrically connected to the reservoirs; anda control circuit for controlling electrotransport current, the control circuit including a patient-controlled switch which activates the device and wherein the reservoir, the power source and the control circuit deliver solely by electrotransport a dose of about 20 .mu.g to about 60 .mu.g of fentanyl over a predetermined delivery period of up to about 20 minutes and terminate said delivery at the end of said delivery period, and wherein the control circuit allows the patient to self-administer from about 10 to about 100 additional of said doses over a period of 24 hours.